Subscribe
Core coverageSRPT

Company profile / SRPT

Sarepta Therapeutics

Clinaptis stanceCautious
ConvictionMedium
Ticker
SRPT
Exchange
NASDAQ
Coverage
Standard profile
Updated
Sep 25, 2026
Genetic Medicine / Neuromuscular

Commercial genetic-medicine company with three exon-skipping therapies and ELEVIDYS in Duchenne muscular dystrophy, plus an early clinical siRNA pipeline in muscle and neurological disease.

01 / Clinaptis view

The current read

Initial read: cautious, but no longer dismissive at roughly $18–19 per share. Sarepta is now a cash-flow transition story built on a durable PMO franchise, a much smaller and more volatile ELEVIDYS opportunity, and early siRNA optionality—not the broad gene-therapy growth story investors owned before the 2025 safety events.

  1. Second-quarter 2026 net product revenue was $328.7 million: $230.6 million from the three PMOs and $98.1 million from ELEVIDYS. PMO revenue was essentially flat year over year, while ELEVIDYS fell by roughly two-thirds after the label was restricted to ambulatory patients aged four years and older; narrowed 2026 product-revenue guidance of $1.2–1.3 billion implies $541–641 million in the second half after $659 million in the first.
  2. Cost cuts have made the reduced revenue base operable: Q2 produced $13.3 million of GAAP operating income and $86.5 million of non-GAAP operating income, although GAAP net income was still slightly negative. June liquidity was $945 million against $848 million of long-term debt, but the headline net-cash view is too generous because the balance sheet also carries about $1.13 billion of inventory, much of it accumulated for a larger ELEVIDYS franchise.
  3. The new upside case is the αvβ6-targeted siRNA platform. SRP-1001 and SRP-1003 have shown dose-dependent muscle exposure, early target knockdown and no dose-limiting toxicity in small Phase 1/2 cohorts, but the 2H26 multiple-ascending-dose readouts must establish reproducible pharmacodynamic depth before these programs deserve material clinical value.
  4. ELEVIDYS should be underwritten as a constrained ambulatory product with a boxed warning for serious liver injury and acute liver failure, weekly post-infusion monitoring and uneven quarterly revenue—not as a return to the pre-2025 addressable market. At the current equity value of roughly $1.9 billion, the stock can work if the PMO base remains stable, ELEVIDYS settles near a sustainable run rate and one siRNA program becomes credible; it does not require a restoration of the old gene-therapy thesis.
02 / Consensus gap

Where the market may differ

The easy bull case is that a company guiding to $1.2–1.3 billion of 2026 product revenue is mispriced at roughly $1.9 billion of equity value. The harder question is how much of that revenue deserves a durable multiple after separating PMOs, ELEVIDYS and one-time collaboration economics.

  1. The PMO franchise supplied about 70% of Q2 product revenue and is the financial anchor, but all three products remain accelerated approvals; ESSENCE missed its primary endpoint even though numerical, biomarker and real-world analyses support treatment. FDA decisions on converting AMONDYS 45 and VYONDYS 53 to traditional approval on February 28, 2027 therefore matter more for franchise durability than for near-term growth.
  2. ELEVIDYS still has value in ambulatory Duchenne, but Q2 revenue was supported by patients who entered the funnel before the revised label and management expects Q3 to be lower. The market may be too pessimistic if enhanced immunosuppression and real-world safety data rebuild physician confidence, but non-ambulatory use should carry no base-case value until prospective evidence and FDA action exist.
  3. The siRNA pipeline creates genuine strategic optionality, not yet a replacement franchise. Early muscle exposure and target knockdown answer delivery questions; they do not yet answer dose durability, functional efficacy, chronic safety or competitive differentiation in FSHD1 and DM1.
  4. Clinaptis would become more constructive on clean, dose-responsive MAD biomarker data plus PMO revenue stability, and more negative if PMOs begin to erode while ELEVIDYS inventory and debt absorb the cash generated by the restructuring.
Coverage state
Standard profile
What the review turns on
Key variable

Whether stable PMO cash flows and a sustainable ambulatory ELEVIDYS run rate can fund the siRNA transition without inventory, debt and regulatory obligations consuming the apparent valuation discount

Next catalyst

SRP-1001 / SRP-1003 · Multiple-ascending-dose FSHD1 and DM1 data · 2H 2026; AMONDYS 45 / VYONDYS 53 · FDA PDUFA · Feb 28, 2027

03 / Pipeline

Key programs

5 assets · 8 programs

AssetIndicationStageNext event
ELEVIDYS
Ambulatory Duchenne muscular dystrophy, age 4+
Commercial · boxed warning
3Q26 revenue and demand stabilizationTrack new starts, ambulatory treatment funnel, liver-safety monitoring and Phase 4 ENDURE data.
PMO franchise
EXONDYS 51 · DMD amenable to exon 51 skipping
Commercial
Quarterly revenue and patient persistencePMOs remain the cash-flow anchor after contributing $230.6 million in Q2 2026.
AMONDYS 45 · DMD amenable to exon 45 skipping
PDUFA · Feb 28, 2027
Feb 28, 2027 · FDA actionESSENCE missed its primary endpoint; FDA is reviewing the totality of biomarker, real-world and safety evidence.
VYONDYS 53 · DMD amenable to exon 53 skipping
PDUFA · Feb 28, 2027
Feb 28, 2027 · FDA actionConversion would reduce the confirmatory-evidence overhang for the commercial PMO base.
SRP-1001 / SRP-1003
SRP-1001 · FSHD1
Phase 1/2
2H26 · FSHD1 MAD readoutJudge dose-dependent DUX4 knockdown, muscle exposure, durability and chronic tolerability.
SRP-1003 · Myotonic dystrophy type 1
Phase 1/2
2H26 · DM1 MAD readoutJudge DMPK knockdown, splice correction, exposure, durability and safety.
SRP-1005
Huntington's disease
Phase 1 · dosing
INSIGHTT dose-escalation updateEarly safety and target-engagement evidence will test delivery beyond skeletal muscle.
LGMD AAV programs
SRP-9003 and other limb-girdle muscular dystrophies
Paused
No near-term value assignedMost LGMD programs were deprioritized after the 2025 AAVrh74 safety events and restructuring.
04 / Connected research

Published on SRPT

View full archive
No published research attached

The profile is live. The research connection is still open.

When a Clinaptis article includes SRPT in its research metadata, it will appear here automatically.

Browse all research